Virucidal Nanoparticles And Use Thereof Against Influenza Virus

Abstract

The invention relates to virucidal nanoparticles comprising a trisaccharide moiety and use thereof against influenza virus.

1 . A virucidal nanoparticle comprising a core and a plurality of ligands covalently linked to the core, wherein at least a portion of said ligands comprise a trisaccharide moiety and wherein:
 the core is cyclodextrin,   the ligands are the same or different and are optionally substituted alkyl-based ligands, and   each trisaccharide moiety is selected from 3-sialyl-N-acetyllactoseamine (3′SLN) and 6-sialyl-N-acetyllactoseamine (6′SLN).   
     
     
         2 . The virucidal nanoparticle of  claim 1 , wherein cyclodextrin is selected from the group consisting of alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, and a combination thereof. 
     
     
         3 . The virucidal nanoparticle of  claim 1 , wherein the ligands are optionally substituted C 4 -C 30  alkyl-based ligands. 
     
     
         4 . The virucidal nanoparticle of  claim 1 , wherein the ligands are optionally substituted C 6 -C 15  alkyl-based ligand compounds. 
     
     
         5 . The virucidal nanoparticle of  claim 1 , wherein some or all of said ligands comprise 3′SLN, some or all of said ligands comprise 6′SLN, and some but not all of said ligands comprise no trisaccharide moiety. 
     
     
         6 . A virucidal nanoparticle represented by Formula (I) 
       
         
           
           
               
               
           
         
       
       wherein
 m is 2 to 8, and 
 n is 2 to 28 or 4 to 13. 
 
     
     
         7 . The virucidal nanoparticle of  claim 6 , wherein cyclodextrin is selected from the group comprising alpha-cyclodextrin, beta-cyclodextrin, and gamma-cyclodextrin. 
     
     
         8 . The virucidal nanoparticle of  claim 6 , wherein m is 3 or 4. 
     
     
         9 . A virucidal nanoparticle represented by Formula (II) 
       
         
           
           
               
               
           
         
       
       wherein:
 each R, independently, is an optionally substituted alkyl-based ligand, wherein at least two of said ligands have a trisaccharide moiety selected from the group comprising 3-sialyl-N-acetyllactoseamine (3′SLN) and 6-sialyl-N-acetyllactoseamine (6′SLN), or wherein at least one of said ligands has 3′SLN and another has 6′SLN; 
 each R′, independently, is H, —(CH 2 ) y —COOH, —(CH 2 ) y —SO 3   − , a polymer or a water solubilizing moiety; 
 x is 6, 7 or 8; and 
 y is an integer from 4 to 20, 
 
       or a pharmaceutically acceptable salt thereof. 
     
     
         10 . The virucidal nanoparticle of  claim 9 , wherein R′ is H. 
     
     
         11 . The virucidal nanoparticle of  claim 9 , wherein said alkyl-based ligands are optionally substituted C 4 -C 30  alkyl-based ligands. 
     
     
         12 . The virucidal nanoparticle of  claim 9 , wherein the alkyl-based ligands are optionally substituted C 6 -C 15  alkyl-based ligands comprising 6′SLN. 
     
     
         13 . A pharmaceutical composition comprising an effective amount of one or more virucidal nanoparticles of  claim 1  and at least one pharmaceutically acceptable excipient, carrier and/or diluent. 
     
     
         14 . A method of treating and/or preventing an influenza virus infection and/or a disease associated with an influenza virus, the method comprising administering to a subject in need thereof a therapeutically effective amount of one or more virucidal nanoparticles of  claim 1 . 
     
     
         15 . A virucidal composition comprising an effective amount of one or more virucidal nanoparticles of  claim 1  and optionally at least one suitable aerosol carrier. 
     
     
         16 . A method of disinfection and/or sterilization comprising contacting a surface with the virucidal nanoparticle of  claim 1 . 
     
     
         17 . A device comprising one or more virucidal nanoparticles of  claim 1  and means for applying or dispensing the virucidal nanoparticles. 
     
     
         18 . (canceled)